Nerve cells communicate with each other through nerve processes or neurites. The dysfunction of neurites results in the clinical symptoms of dementia such as cognitive decline. Currently we cannot directly monitor degeneration of neurites in the living brain and therefore it is difficult to determine whether therapeutic agents are protective. My goal is to develop a detection system in the blood that will allow us to monitor these changes during disease progression and therapeutic intervention.
Implications Of Retinal Neurodegeneration In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$602,213.00
Summary
Recent research has shown that “early signs” of Alzheimer ’s disease (AD) can be detected in the eyes. My research focus is to determine which particular changes in the retina are associated with AD. I will also investigate if blocking the production of beta amyloids (proteins produced in AD) in the eye will indeed help reduce their load in the brain and hence delay the onset of AD. Results from this research maybe used for early diagnosis and future medicinal studies that target the eye in AD.
Cognition In Motion: Characterization And Evolution Of Cognitive Dysfunction In Motor Neurodegeneration And Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$604,106.00
Summary
Motor neuron disease (MND) is a fatal disease. Cognition may be unaffected or may be severely impaired to warrant a dementia diagnosis. The cognitive status at onset, its progression and the presence of co-morbid dementia of most MND patients is unknown. This research program will develop and validate a cognitive screener that diagnosis co-morbid dementia in the context of motor neurodegeneration in MND.
BRAIN-MEND: Biological Resource Analysis To Identify New Mechanisms And Phenotypes In Neurodegenerative Diseases
Funder
National Health and Medical Research Council
Funding Amount
$861,866.00
Summary
Current classification of neurodegenerative diseases (ND) based on clinical phenotypes does not take into account underlying disease heterogeneity, or overlapping disease mechanisms, thus hindering therapy development. Segregation and re-classification of ND phenotypes is urgently needed. BRAIN-MEND will reclassify existing phenotypic classifications using using pathway and network analyses within and across complex NDs.
Restoring Defective Protein Homeostasis In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
Frontotemporal dementia (FTD) is associated with pathological accumulation and aggregation of toxic proteins in affected brain regions. This project will employ a novel high throughput drug screening platform technology, FTD patient-derived nerve cells and genetic mouse models to screen drugs to improve clearance of toxic proteins and nerve cell health. This approach should accelerate discovery of agents to potentially treat the underlying cause of FTD in an effort to slow disease progression.
Targeting Inflammation As A Biomarker And Treatment For Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$718,920.00
Summary
We are undertaking the challenge of using and developing novel animal models in parallel with studies on affected human subjects to elucidate the underlying molecular mechanisms linking the changes in inflammation to amyloid plaques, neurofibrillary tangles and cognitive decline. Understanding these mechanisms will allow us to define the biological pathways involved in the onset and progression of Alzheimer’s disease, and identify potential biomarkers and therapeutic targets.
Targeting Neuroinflammatory Pathways As Novel Treatments For Dementia
Funder
National Health and Medical Research Council
Funding Amount
$600,116.00
Summary
Australia has a rapid increase in its ageing population, and consequently an increase in detrimental age-related dementia and neurodegenerative diseases which are a major healthcare burden. Current treatments for diseases such as Alzheimer’s, Parkinson’s and Huntington’s are inadequate and there is a desperate need for new treatments. I have unique access to molecules that target two novel mechanisms for neurodegenerative diseases. This fellowship will explore their therapeutic potential.
The Role Of Oligodendrocytes In Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$625,292.00
Summary
Dementia affects 35.6 million people world-wide; this number is projected to double every 20 years. Frontotemporal dementia (FTD) is the second most common type and has been found to have similar cause and pathology to common neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). We ultimately require treatments to slow, stop and repair the damaged brain of FTD patients and this is only possible by understanding the mechanisms involved in the onset and progression of disease.
A European DNA Bank For Deciphering The Missing Heritability Of Alzheimer's Disease (EADB)
Funder
National Health and Medical Research Council
Funding Amount
$1,556,995.00
Summary
Understanding the genetics of Alzheimer’s disease (AD) is one of the best ways of improving our knowledge of the underlying mechanisms of disease development. There is evidence that genetic factors account for up to 80% of the risk for AD. Recent advances in genetics still explain <50% of this risk. This proposal will help two major Australian studies to partner with a large European consortium in trying to understand the “missing” heritability, using existing and novel genetic data.
NOX Enzymes As Mediators Of Inflammation-triggered Neurodegeneration: Modulating NOX Enzymes As Novel Therapies
Funder
National Health and Medical Research Council
Funding Amount
$994,846.00
Summary
The NEURINOX project aims at identifying novel therapeutic targets for neurodegenerative diseases; an increasing health issue for the ageing Australian population. NADPH oxidases (NOX) enzymes, generate reactive oxygen species, and are key regulators of neuroinflammation. Inflammatory dysregulation is characterized by a change in NOX activity. NEURINOX will expound the links between neuroinflammation, NOX enzyme activity & neurodegenerative diseases to identify novel therapeutic targets to treat ....The NEURINOX project aims at identifying novel therapeutic targets for neurodegenerative diseases; an increasing health issue for the ageing Australian population. NADPH oxidases (NOX) enzymes, generate reactive oxygen species, and are key regulators of neuroinflammation. Inflammatory dysregulation is characterized by a change in NOX activity. NEURINOX will expound the links between neuroinflammation, NOX enzyme activity & neurodegenerative diseases to identify novel therapeutic targets to treat neuroinflammation.Read moreRead less